{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:38:42Z","timestamp":1758040722951,"version":"3.44.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Aventis Pharmaceuticals"},{"DOI":"10.13039\/100004339","name":"sanofi-aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AstraZeneca"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.amjmed.2009.09.001","type":"journal-article","created":{"date-parts":[[2010,1,25]],"date-time":"2010-01-25T02:04:41Z","timestamp":1264385081000},"page":"103-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Thrombin Hypothesis in ACS: A Disappointing Disconnect between Bench Data and Bedside Clinical Trials"],"prefix":"10.1016","volume":"123","author":[{"given":"Marc","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2009.09.001_bib1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.1996.03540100055028","article-title":"Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina","volume":"276","author":"Oler","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2009.09.001_bib2","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/eurheartj\/ehm224","article-title":"Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis","volume":"28","author":"Murphy","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2009.09.001_bib3","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2009.09.001_bib4","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2009.09.001_bib5","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2009.09.001_bib6","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.pcad.2004.02.002","article-title":"Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors","volume":"46","author":"Kokolis","year":"2004","journal-title":"Prog Cardiovasc Dis."},{"key":"10.1016\/j.amjmed.2009.09.001_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1023\/A:1018710526772","article-title":"Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization","volume":"9","author":"Spencer","year":"2000","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.amjmed.2009.09.001_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI114723","article-title":"Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors","volume":"86","author":"Weitz","year":"1990","journal-title":"J Clin Invest."},{"key":"10.1016\/j.amjmed.2009.09.001_bib9","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1055\/s-0038-1648947","article-title":"The influence of fibrinogen and fibrin on thrombin generation--evidence for feedback activation of the clotting system by clot bound thrombin","volume":"72","author":"Kumar","year":"1994","journal-title":"Thromb Haemost."},{"issue":"1 Suppl","key":"10.1016\/j.amjmed.2009.09.001_bib10","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.ahj.2004.10.022","article-title":"Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors","volume":"149","author":"Gurm","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2009.09.001_bib11","unstructured":"Alexander J. Safety of the factor Xa inhibitor, Apixaban, in combination with antiplatelet therapy after acute coronary syndrome: results of the APPRAISE-1 dose guiding trial. Late-breaking abstract. European Society of Cardiology (ESC) Congress, 30 Aug 2008-03 Sep 2008, Munich, Germany."},{"key":"10.1016\/j.amjmed.2009.09.001_bib12","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1161\/CIRCULATIONAHA.106.653428","article-title":"Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial","volume":"115","author":"Cohen","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2009.09.001_bib13","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/hc0802.104331","article-title":"Direct thrombin inhibitors in acute coronary syndromes: present and future","volume":"105","author":"Weitz","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2009.09.001_bib14","doi-asserted-by":"crossref","first-page":"V275","DOI":"10.1016\/S0049-3848(02)00093-2","article-title":"Direct thrombin inhibitors","volume":"106","author":"Weitz","year":"2002","journal-title":"Thromb Res."},{"key":"10.1016\/j.amjmed.2009.09.001_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.hoc.2004.09.002","article-title":"The direct thrombin inhibitors: their role and use for rational anticoagulation","volume":"19","author":"Frenkel","year":"2005","journal-title":"Hematol Oncol Clin North Am."},{"key":"10.1016\/j.amjmed.2009.09.001_bib16","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/01.CIR.82.2.570","article-title":"Heparin-resistant thrombus formation by endovascular stents in baboons","volume":"82","author":"Krupski","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2009.09.001_bib17","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0025-6196(12)61201-4","article-title":"The porcine model for the understanding of thrombosis and atherogenesis","volume":"66","author":"Fuster","year":"1991","journal-title":"Mayo Clinic Proc."},{"key":"10.1016\/j.amjmed.2009.09.001_bib18","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/01.CIR.97.7.681","article-title":"Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin","volume":"97","author":"Meyer","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2009.09.001_bib19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1160\/TH07-02-0113","article-title":"Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats","volume":"98","author":"Wienen","year":"2007","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.amjmed.2009.09.001_bib20","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1538-7836.2007.02526.x","article-title":"Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis","volume":"5","author":"Wienen","year":"2007","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.amjmed.2009.09.001_bib21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-0038-1648875","article-title":"Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin","volume":"72","author":"Berry","year":"1994","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.amjmed.2009.09.001_bib22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/107602960100700303","article-title":"Anticoagulation: the present and future","volume":"7","author":"Van Aken","year":"2001","journal-title":"Clin Appl Thromb Hemost."},{"issue":"Suppl 3","key":"10.1016\/j.amjmed.2009.09.001_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000069103","article-title":"An overview of the direct thrombin inhibitor argatroban","volume":"32","author":"Walenga","year":"2002","journal-title":"Pathophysiol Haemost Thromb."},{"key":"10.1016\/j.amjmed.2009.09.001_bib24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1055\/s-2007-996129","article-title":"Development of argatroban, a direct thrombin inhibitor, and its clinical application","volume":"23","author":"Matsuo","year":"1997","journal-title":"Semin Thromb Hemost."},{"key":"10.1016\/j.amjmed.2009.09.001_bib25","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0735-1097(99)00107-2","article-title":"A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study","volume":"33","author":"Jang","year":"1999","journal-title":"J Am Coll Cardiol."},{"issue":"Suppl 17","key":"10.1016\/j.amjmed.2009.09.001_bib26","first-page":"I453","article-title":"Argatroban versus heparin as adjuvant therapy to thrombolysis for acute myocardial infarction: safety considerations\u2014ARGAMI-2 Study","volume":"98","author":"Behar","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2009.09.001_bib27","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0002-9149(98)00069-1","article-title":"Heparin is more effective than inogatran, a low-molecular-weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease","volume":"81","author":"Andersen","year":"1998","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.amjmed.2009.09.001_bib28","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0002-8703(99)70185-7","article-title":"Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction","volume":"138","author":"Fung","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2009.09.001_bib29","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2009.09.001_bib30","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0735-1097(03)00255-9","article-title":"Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation","volume":"41","author":"Petersen","year":"2003","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.amjmed.2009.09.001_bib31","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199609123351103","article-title":"A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes","volume":"335","year":"1996","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2009.09.001_bib32","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.CIR.94.5.911","article-title":"Hirudin in acute myocardial infarction","volume":"94","author":"Antman","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2009.09.001_bib33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(02)07495-0","article-title":"Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data","volume":"359","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2009.09.001_bib34","doi-asserted-by":"crossref","first-page":"12P","DOI":"10.1016\/S0002-9149(98)00660-2","article-title":"Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin","volume":"82","author":"Bates","year":"1998","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.amjmed.2009.09.001_bib35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1067\/mcp.2002.124522","article-title":"Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, doses, and gender","volume":"71","author":"Robson","year":"2002","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.amjmed.2009.09.001_bib36","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina","volume":"333","author":"Bittl","year":"1995","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2009.09.001_bib37","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2009.09.001_bib38","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.298.21.2497","article-title":"Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial","volume":"298","author":"Stone","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2009.09.001_bib39","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(01)06887-8","article-title":"Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial","volume":"358","author":"White","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2009.09.001_bib40","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention","volume":"359","author":"Kastrati","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2009.09.001_bib41","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2009.09.001_bib42","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/sj.bjp.0704182","article-title":"Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis","volume":"133","author":"Rebello","year":"2001","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.amjmed.2009.09.001_bib43","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.clpt.2006.09.002","article-title":"Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease","volume":"80","author":"Hinder","year":"2006","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.amjmed.2009.09.001_bib44","unstructured":"Study of otamixaban versus unfractionated heparin and eptifibatide in non-ST elevation acute coronary syndrome (SEPIA-ACS 1). ClinicalTrials.gov identifier: NCT00317395. Available at: www.clinicaltrials.gov."},{"key":"10.1016\/j.amjmed.2009.09.001_bib45","first-page":"2309","article-title":"Randomized comparison of rivaroxaban, an oral direct factor Xa inhibitor, with placebo in patients with acute coronary syndromes: the ATLAS ACS-TIMI 46 trial","volume":"118","author":"Gibson","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2009.09.001_bib46","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1055\/s-0037-1613294","article-title":"Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin","volume":"88","author":"Shimbo","year":"2002","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.amjmed.2009.09.001_bib47","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1111\/j.1538-7836.2004.01040.x","article-title":"Inhibition and reversal of platelet-rich arterial thrombus in vivo: direct vs. indirect factor Xa inhibition","volume":"2","author":"Karnicki","year":"2004","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.amjmed.2009.09.001_bib48","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2009.09.001_bib49","first-page":"45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2009.09.001_bib50","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.ahj.2006.08.002","volume":"152","author":"White","year":"2006","journal-title":"Am Heart J."},{"key":"10.1016\/j.amjmed.2009.09.001_bib51","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","article-title":"Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction","volume":"354","author":"Antman","year":"2006","journal-title":"N Engl J Med."},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2009.09.001_bib52","first-page":"A204","article-title":"Predictors of excessive anticoagulation with unfractionated heparin in STEMI","volume":"51","author":"Cheng","year":"2008","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.amjmed.2009.09.001_bib53","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2007.02.027","article-title":"Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial","volume":"49","author":"Manoukian","year":"2007","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.amjmed.2009.09.001_bib54","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934309007724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934309007724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:52:24Z","timestamp":1757580744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934309007724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0002934309007724"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2009.09.001","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Thrombin Hypothesis in ACS: A Disappointing Disconnect between Bench Data and Bedside Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2009.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}